Novartis Acquires Rremaining Rghts to GSK's Ofatumumab to Develop Treatments for MS, Other Autoimmune Indications
August 21, 2015 at 04:34 AM EDT
Novartis (NYSE: NVS) announced today that it has entered into an agreement to acquire all remaining rights to Ofatumumab from ...